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Killing bacteria within biofilms by sustained release of tetracycline from triple-layered 
electrospun micro/nanofibre matrices of polycaprolactone and poly(ethylene-co-vinyl 
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Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK 
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Abstract  We report the controlled release of the antibiotic tetracycline (tet) HCl from a triple-
layered electrospun matrix consisting of a central layer of poly(ethylene-co-vinyl acetate (PEVA) 
sandwiched between outer layers of poly-Ɛ-caprolactone (PCL).  These micro/nanofibre layers 
with tet successfully encapsulated (essentially quantitatively at 3% and 5% w/w) in each layer, 
efficiently inhibited the growth of a panel of bacteria, including clinical isolates, as shown by a 
modified Kirby-Bauer disc assay.  Furthermore, they demonstrated high biological activity in 
increasingly complex models of biofilm formation (models that are moving closer to the situation 
in a wound) by stopping biofilm formation, by killing preformed biofilms, and killing mature, 
dense biofilm colonies of S. aureus MRSA252.  Tet is clinically useful with potential applications 
in wound healing and especially in complicated skin and skin-structure infections; electrospinning 
provides good encapsulation efficiency of tet within PCL/PEVA/PCL polymers in micro/ 
nanofibre layers which display sustained antibiotic release in formulations that are anti-biofilm. 
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Introduction 
 
Chronic wounds, such as diabetic ulcers, are hard to heal and require prolonged treatment due to a 
number of clinical complications, including coagulated proteins and the avascular nature of the 
eschar around the wound [1, 2].  Consequences of reduced blood irrigation are a restriction of the 
delivery of the host’s immune cells and of systemically administered antibiotics [2].  There has 
been an increasing interest in the topical application of antimicrobials to overcome the problems 
associated with the low levels of antibiotic in the granulating tissue [2].  In wound treatment, there 
may also be a desire to leave dressings on for extended periods, as that will minimise damage to 
newly formed tissue.  However, application of topical antimicrobials requires daily or twice-daily 
changes of the dressing, leading to patient discomfort as well as being time consuming and costly.  
In recent years there has therefore been a considerable interest in dressings that allow for a 
controlled release of antimicrobials [3]. 
Sadly, infections in chronic wounds are common and they often involve biofilms [4].  That 
microbial communities exist as biofilms has been demonstrated using light and scanning electron 
microscopy in 60% of chronic wounds e.g. foot ulcers, pressure ulcers, venous leg ulcers, and 
ulcerated burn wounds [5, 6].  Biofilms are communities of bacterial cells that are attached to 
biotic or abiotic surfaces.  Cells in these biofilms are enveloped in a matrix of extracellular 
substance that may include polysaccharides, proteins, and/or DNA, providing protection against 
different environmental conditions [7-9].  We now know that biofilms are prevalent in nature and 
indeed appear to be associated with the majority of infections, e.g. wound infections, catheter-
linked infections, endocarditis, dental caries, and cystic fibrosis [10].  A particular problem of 
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bacteria within biofilms is that they are significantly more resistant to antibiotics compared to 
their free-floating planktonic counterparts [11].  There are several reasons for this, including the 
slow growth rates of bacteria in biofilms, the reduced penetration of antibiotics (e.g. through 
production of antibiotic-degrading enzymes), and/or cell density-regulated overproduction of 
efflux pumps [12].  In addition, cells in biofilms are more resistant to attack by the host’s immune 
system [9], and several pathogens, irrespective of whether they form biofilms or not, have 
acquired additional resistance mechanisms against antibiotics that are used clinically.  Taken 
together, biofilm-related infections are difficult to treat and eradicate.  If left untreated, bacterial 
infections in wounds may lead to an invasive wound infection and the possibility of sepsis [13].  
Thus, it is important to reduce the bioburden in a wound in order to speed up the healing process.  
In wounds where antibiotic treatment is needed, localized antibiotic delivery systems may 
overcome the problems associated with the low antibiotic levels in the granulating tissue [2].  As a 
result of the increased resistance of biofilms to treatment by antibacterial agents, a need has 
emerged to test the biological activity of antibacterial wound dressings against biofilms rather 
than against planktonic bacteria.  Such models are more relevant to how the bacteria exist in 
chronic wounds and hence to translational research. 
We have recently developed formulations in which tetracycline (tet) HCl has been 
successfully incorporated in multi-layered electrospun micro/nanofibre matrices of 
polycaprolactone (PCL) and poly(ethylene-co-vinyl acetate) (PEVA).  Its controlled release was 
demonstrated from the triple-layer (3L) matrix PCL/PEVA/PCL (with 3% w/w tet in each layer, 
3L+tet 3%), without loss of chemical stability or bioactivity [14].  The matrices were prepared by 
electrospinning, a very promising technique for many biomedical applications e.g. tissue 
engineering and drug delivery systems [15, 16].  The electrospun fibrous matrix was able to 
sustain the release of tet over more than 15 days [14].  Furthermore, we demonstrated the 
bioactivity of the released tet against Staphylococcus aureus (ATCC 25923) using an 
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antimicrobial susceptibility test for 5 days [14].  We are therefore working towards establishing 
that this novel matrix is suitable for applications in wound dressings [17].  In order to make 
further progress from our fundamental research towards the clinic, it is important to evaluate the 
effectiveness of our antibiotic formulations against a wider panel of bacteria and with a focus on 
biofilm-forming S. aureus MRSA252.  We have verified the activity of our 3L+tet 3% sustained 
release matrix against five clinical isolates and a further three laboratory strains.  The bacteria 
tested included pathogens that very commonly cause nosocomial infections, such as 4ethicillin-
resistant S. aureus (MRSA).  S. aureus is one of the most important pathogens responsible for 
post-surgical and life-threatening bloodstream infections [18, 19].  In addition, S. aureus attaches 
effectively to both biotic and abiotic surfaces, e.g. catheters and prosthetic joints, and then forms 
biofilms [20].  We have therefore also investigated a higher concentration 3L+tet 5% sustained 
release matrix.  As highlighted above, chronic wound infections usually involve biofilms rather 
than planktonic cells, and it is therefore important to test the controlled release matrices against 
bacterial biofilms.  So we also report assays designed to test the levels of antibacterial activity 
achieved in a series of models of selected wound-associated biofilms of increasing complexity. 
 
Materials 
 
Poly-Ɛ-caprolactone (PCL) (Mn 70 000-90 000), poly(ethylene-co-vinyl acetate) (PEVA) (40 wt 
% vinyl acetate), tetracycline (tet) HCl, and other chemicals, solvents, and membrane filters for 
epifluorescent microscopy (polycarbonate discs, pore size 0.2 µm, diameter 13 mm) were 
purchased from Sigma-Aldrich.  Müller-Hinton (MH) agar, MH broth, Tryptone Soya broth 
(TSB), and antimicrobial tetracycline HCl susceptibility test discs were purchased from Oxoid.  
Luria-Bertani (LB) broth was purchased from Fisher.  Crystal violet 1% was purchased from 
PRO-LAB Diagnostics.  RINZLE (polyvinyl) plastic coverslips were purchased from Electron 
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Microscopy Sciences.  LIVE/DEAD® BacLight Bacterial Viability Kits were purchased from 
Molecular Probes.  Polystyrene 96-well plates (flat bottom, volume 0.36 mL, well diameter 7 mm) 
were purchased from Costar.  Filter discs were cut from Whatman 3MM Chr cellulose 
chromatography paper (0.34 mm thickness). 
 
Methods 
 
Polymer solutions 
 
PCL was dissolved to a fixed concentration of 12% (w/v) in a 9:1 (v/v) mixture of chloroform 
(CHCl3) and methanol (MeOH).  Tet was dissolved in the MeOH at 5% of the weight of the 
polymer.  PEVA solution was similarly prepared at 12% (w/v) in CHCl3/MeOH (9:1, v/v) and tet 
(5% of the weight of PEVA) was likewise incorporated in the MeOH. 
 
Micro/nanofibre fabrication via electrospinning 
 
Each polymer solution was loaded into a syringe and electrospun at 16.5 kV and a flow rate of 1.5 
mL/h, with a distance between the tip of the needle and the collector of 13 cm.  The flow rate was 
controlled by a syringe infusion pump (Cole Parmer).  The electrospun micro/nanofibrous 
matrices were collected on two parallel metal electrodes covered with aluminium foil.  To 
fabricate layered mats, each polymer solution was electrospun for a fixed deposition time (40 min) 
in a layer-by-layer manner.  After 20 min, the rectangular collector was rotated through 180° for a 
second collection of 20 min.  Two formulations were designed:  a single layer PCL matrix with 
5% tet (single layer 5%), and a triple layer PCL/PEVA/PCL matrix with 5% tet in each layer 
(3L+tet 5%).  The 3L+tet 3% matrices were prepared as previously described [14]. 
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Morphology 
 
The surface morphology and cross-sections of the layered electrospun matrices were observed by 
scanning electron microscopy (SEM).  The matrices were cut into small, centimetre-sized pieces, 
and cross-sections of the layers obtained were freeze fractured in liquid nitrogen.  The samples 
were sputter coated with gold (Edwards Sputter Coater 5150B) and then analysed by SEM (JEOL 
JSM-6480LV) with an accelerating voltage from 15 kV.  The average fibre diameter was 
determined in layered electrospun matrices containing tet (5%).  Some fibre diameter 
measurements were also taken after drug release (14 days) for comparison.  The average fibre 
diameter was determined by randomly selecting 20 fibres per image from 3 SEM images and 
measuring their diameters using ImageJ software (NIH, Bethesda, MD; http://rsb.info.nih.gov/ij/).  
The average thickness of each layer was determined by measuring the thickness of the cross-
sections of two SEM images using the same software. 
 
Encapsulation efficiency 
 
To determine the encapsulation efficiency of the nanofibres, tet-containing electrospun mats were 
cut into small pieces (∼1 cm2), weighed and then dissolved in CHCl3/MeOH (9:1 (v/v), 10 mL).  
The UV absorbance of each solution was measured at λ = 360 nm, and the amount of tet then 
determined using a tet calibration curve.  Encapsulation efficiency was calculated for each matrix 
as a percentage of the theoretical maximum tet incorporation (5% w/w in each polymer layer; n = 
3, in triplicate). 
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Tet release profile from the triple-layered fibrous matrices 
 
The 3L+tet 3% matrices were cut into 4 cm2 squares and each 3% sample was placed in PBS 
buffer (10 mL; pH = 7.4) in a glass vial.  The 5% micro/nanofibrous matrices were punched into 
circles with diameter of 0.9 cm.  Each 5% sample was placed in PBS buffer (5 mL; pH = 7.4) in a 
plastic vial.  The vials were incubated at 37 °C.  At specific time intervals (typically 24 h), the 
buffer (5 or 10 mL) was changed around each matrix sample.  The release buffer samples were 
assayed by UV spectroscopy at λ = 360 nm and the amount of tet released at each specific time 
was then calculated using a tet calibration curve and subsequently compared to the theoretical 
value (3% or 5%) (n = 3, in triplicate). 
 
Bacterial strains and growth conditions 
 
The bacterial strains used in this study were Bacillus subtilis 168 [21], Escherichia coli NTB5 
[22], Enterococcus faecalis ATCC 19433 (www.atcc.org), E. faecalis BS385 [23], Pseudomonas 
aeruginosa NCTC 6750 (www.hpacultures.org.uk), P. aeruginosa PAO1 [24], Salmonella 
typhimurium NTB6 [22], S. aureus MRSA252 [25].  All strains were maintained in TSB or LB 
broth. 
 
Testing the formulations against a panel of bacteria 
 
The strains listed above were used to investigate the efficacy of the 3L+tet 3% matrix and 
compared to commercially available tet loaded discs and to matrices without tet.  For this analysis, 
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a modified Kirby-Bauer disc assay was used [26].  An overnight culture (16 h) of bacteria was 
diluted with sterile MH broth to obtain an optical density (OD) of about 0.1 at 600 nm.  Then, the 
diluted bacterial suspension (100 µL) was spread onto the surface of an MH agar plate and 6 mm 
circular discs, punched from 3L+tet 3% matrices, were placed on the agar plates.  These discs 
contained 30 µg tet, which is equivalent to the amount of tet in the commercially available discs.  
After incubation at 37 °C for 24 h, the growth inhibition zones around the discs were measured. 
 
Antibacterial efficacy of 3L+tet 5% after 14 days of release 
 
S. aureus MRSA252 was used to investigate the efficacy of tet loaded in 3L+tet 5% matrices.  For 
this, a modified Kirby-Bauer disc assay was used.  An overnight culture (16 h) of bacteria was 
diluted with sterile TSB-GN to obtain an optical density (OD) of 0.015 at 600 nm.  Then, the 
diluted bacterial suspension (200 µL) was spread onto the surface of an MH agar plate and discs, 
punched from 3L+tet 5% matrices, retrieved following 14 days of tet release, were placed on the 
agar plates.  These discs initially contained ~270 µg tet, whereas the amount of tet in the 
commercially available discs was 30 µg (n = 3, in duplicate).  After incubation at 37 °C for 24 h, 
the growth inhibition zones around the discs were measured. 
 
Biofilms studies 
 
96-Well microtiter plate (MTP) biofilm assay 
 
The experiment was carried out as described elsewhere with some minor modifications [22].  S. 
aureus MRSA252 was cultured (15 h) in TSB containing 0.5% glucose and 3% NaCl (TSB-GN) 
and diluted 20-fold.  To investigate the ability of the triple-layer matrix (3L+tet 3% matrix) to 
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prevent the formation of biofilms, 200 µL/well of the diluted bacterial suspension was dispensed 
into a polystyrene 96-well plate in 5 groups, with 6 replicates each:  a group of matrices (6 mm 
diameter) containing 30 µg tet (3L+tet 3%), a group of matrices containing no tet (PCL no tet), a 
group of 30 µg/well tet solution in TSB-GN, a negative control group (media + 30 µg/well tet 
solution in TSB-GN, without bacteria), and a positive control group containing a diluted bacterial 
suspension only.  The plates were incubated for 24 h at 37 ºC on a 3-dimensional plate rotator (40 
rpm).  The cell suspension was removed and biofilms were washed with sterile PBS (3 x 200 
µL/well).  The plates were dried for 1 h at 20 °C, and biofilms were then stained with crystal 
violet solution (1% w/v).  After 15 min, the excess of crystal violet and the matrices were 
removed, plates were washed briefly with water (4 x 250 mL), and the crystal violet was dissolved 
in aqueous acetic acid (30% v/v in distilled water).  The absorbance, representative of the amount 
of biofilm formed, was measured at λ = 595 nm (A595). 
To test the ability of the triple-layer matrix to eradicate preformed biofilms, 200 µL/well 
of diluted bacterial suspension (S. aureus MRSA252) was dispensed into a polystyrene 96-well 
plate in 5 groups, with 6 replicates, and the plates were incubated for 24 h at 37ºC on a 3-
dimensional plate rotator (40 rpm).  The cell suspension was removed and biofilms were washed 
carefully with PBS (1 x 200 µL).  Fresh TSB-NG (200 µL) was added to each well, and then 
matrices or tet solution were added to groups of wells:  matrices containing 30 µg tet (3L+tet 3%), 
matrices containing no tet (PCL no tet), tet solution (30 µg/well), a negative control (media + tet 
solution 30 µg/well, without bacteria), and a positive control (diluted bacterial suspension only).  
Plates were incubated again for 24 h at 37 ºC, and the biofilms were then washed and stained as 
above.  The amount of biofilm formed was again quantified by measuring the A595. 
 
Killing biofilms by sustained release Tet 
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To investigate the ability of the matrices to kill formed biofilms in a sustained manner, the discs 
were introduced onto a preformed biofilm of MRSA252 using the MTP model.  The next day, the 
same discs were transferred to a new biofilm, and this was repeated on day 3.  All biofilms were 
washed and quantified with crystal violet as described before.  Further release of tet was analysed 
with a Kirby-Bauer test by transferring the matrices on day four to an MH agar plate streaked with 
MRSA252, and this was repeated with the same discs on day five.  After incubation at 37 °C for 
24 h, the growth inhibition zones around the discs were measured (n = 3, 6 replicates). 
 
Confocal microscopy 
 
The experiment was carried out as described elsewhere, with some minor modifications [27].  S. 
aureus MRSA252 was cultured overnight in TSB-GN, and diluted to an OD at 600 nm of 0.4-0.6.  
Polyvinyl plastic coverslips (22 mm × 22 mm) were sterilized in absolute isopropanol, dried and 
placed in 3 wells of a six-well cell culture plate.  An aliquot (2 mL) of the diluted bacterial 
suspension was added to each well and an aliquot (2 mL) of TSB-GN was added.  The plate was 
placed on a 3D rotator (40 rpm) at 37 °C for 24 h, then the media were aspirated off and an aliquot 
(4 mL) of fresh TSB-GN was added.  The 3L+tet 3% matrices were introduced to the wells (20 
mm × 20 mm, 20 mm × 20 mm filter paper loaded with an equivalent amount of tet (1.14 mg); 
one well was left untreated as a control).  The plate was incubated at 37 0C for another 24 h, then 
the media were aspirated off and the coverslips washed with sterile water (6 x 2 mL).  To assess 
the effectiveness of the matrices, coverslips were stained with LIVE/DEAD BacLight mixture 
(50:50 v/v, 800 µL, 0.3% v/v of each supplied dye solution diluted in sterile water).  To prepare 
the stain from the manufacturer’s stock solutions, SYTO® 9 dye solution (3 µL of 3.34 mM in 
DMSO) was mixed with propidium iodide (3 µL of 20 mM in DMSO) in sterile water (1 mL).  
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The coverslips were left for 15 min in the dark prior to washing with sterile water (6 x 2 mL).  
Then the coverslips were mounted on glass slides using nail varnish. 
 
Colony biofilm model (CBM) 
The experiment was carried out as described elsewhere, with some minor modifications [28].  S. 
aureus MRSA252 was cultured (15 h) in TSB-GN, and diluted to an OD at 600 nm of 0.4-0.6.  
Five sterile 13 mm polycarbonate discs were placed on the surface of MH agar plates and aliquots 
(50 µL) from the diluted bacterial suspension were spotted on to each disc.  Inoculated discs were 
incubated for 72 h at 37 °C to allow formation of the biofilm.  The polycarbonate discs were 
carefully transferred to new agar plates with sterile forceps on a daily basis.  On the fourth day, 
the discs were covered with 3L+tet 3% or 3L+tet 5% (13 mm diameter, 3% and 5% of the weight 
of the 3L mat respectively), a filter paper loaded with the same amount of tet as the 3% sample 
(~390 µg), and a PCL disc containing no tet (as a negative control).  The matrices and the filter 
paper were cut to 13 mm in diameter; the fifth polycarbonate disc was left without any treatment.  
Before covering the discs with the 3L matrices, the surface of the biofilms was wetted with MH 
broth (10 µL) and, after the coverage, another 25 µL of broth was applied on top of the matrices.  
The plates were then incubated again at 37 °C for 24 h and the polycarbonate discs with the 
matrices were then rinsed gently in sterile 0.9% NaCl to remove any cells that were loosely 
attached.  Each disc was then transferred to a tube containing MH broth (5 mL) and kept cool on 
ice during the experiment.  The tubes were vortexed extensively (~3 min) in order to mechanically 
disrupt the biofilms and detach the bacteria from the discs.  Suspended cells were then serially 
diluted to 10-7 in broth and aliquots (10 µL) of 10-4, 10-5, 10-6, and 10-7 dilutions were spotted on 
MH agar plates, to determine the colony forming units (CFU)/mL using the Miles-Misra method 
[29], as shown diagrammatically in Fig. 1.  The plates were incubated at 37 °C for 24 h and the 
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numbers of CFU were counted.  The number of CFU/disc was determined using the following 
formula: 
CFU/disc = CFU counted × dilution factor × 100 × 5; this was then normalised by the number of 
CFU/biofilm disc. 
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Fig. 1.  A sketch describing the colony biofilm model (CBM) experiment. 
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Results and Discussion 
 
Morphology 
 
The SEM images (Fig. 2) show that the electrospun PCL nanofibres remained intact as the 
diameters did not change significantly (e.g. 651 ± 251 and 666 ± 255 nm) before and after tet 
(5%) release (14 days).  Electrospun PEVA fibres had a significantly greater diameter (1678 ± 
1342 nm) than PCL fibres due to the polymer properties [14].  The cross section of the 
electrospun 3L+tet 5% matrix was 257 ± 65 µm. 
 
SIX 6Mb SEM PHOTOS HERE (see other uploaded file) 
 
 
 
 
 
 
Fig. 2.  SEM images of:  a) PCL fibres (single layer) electrospun with tet (5%) with diameter of 
651 ± 251 nm, b) PCL fibres (third layer) electrospun with tet with diameter of 607 ± 336 nm, c) 
PCL fibres (outer layer after release of tet for 14 days) with diameter of 666 ± 255 nm, d) cross 
section of the PEVA fibres (second layer) electrospun with tet with fibre diameter of 1678 ± 1342 
nm, e) cross section of the electrospun triple layered matrix electrospun with tet with total 
thickness of 257 ± 65 µm, first layer’s thickness is 111 ± 18 µm, f) cross section of second layer 
with thickness of 57 ± 30 µm and third layer with thickness of 88 ± 17 µm. 
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Encapsulation efficiency 
 
Tet loading in single layer 5% and 3L+tet 5% matrices were 4.76 ± 0.46 % and 5.3 ± 0.7 %, 
respectively, compared with 5% (w/w) initial strength.  Essentially quantitative drug 
encapsulation efficiencies of 93 ± 8 % and 105 ± 7 %, respectively, were achieved. 
 
In vitro tet release studies 
	    
Fig. 3.  The tet release profile from the electrospun single- and triple-layered fibrous matrices with 
two tet concentrations of 3% and 5% w/w.  The error bars represent the standard deviation of 
release values (n = 3 in triplicate). 
 
The 3L+tet 3% matrix burst release was 55% of the tet within the first 3 h, then the release of the 
remaining antibiotic was sustained to reach ~80% at day 14 (Fig. 3) [14].  Likewise, the 3L+tet 
5% matrix burst release was 67% of the tet within the first 3 h, then the release of the remaining 
antibiotic was sustained to reach ~87% at day 14 (Fig. 3).  This formulated matrix combines the 
release profile properties of the two polymers, PCL and PEVA.  We have demonstrated that a 
nanofibrous mat composed only of PCL burst releases essentially all of its content of tet in the 
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 8 10 12 14 16 
Te
t c
um
ul
at
iv
e 
re
le
as
e 
%
  
Days 
Single Layer 3% 
Single Layer 5% 
3L+tet 3% 
3L+tet 5% 
16 
	  
first 30 min, whereas a PEVA only mat sustains the release of tet for 8 days [14].  For a successful 
antibacterial wound dressing, an initial burst release would help to eliminate any invading 
bacteria, whereas a sustained release of antibiotic will also aid the immune system of the host in 
the prevention of any relapse [30]. 
We have previously reported the antibacterial properties of the 3L+tet 3% matrix against 
S. aureus ATCC 25923 [14].  Here we report similar antibacterial efficacy of 3L+tet 5% matrix 
after 14 days release demonstrating the sustained release of an efficacious amount of tet from this 
formulation (Fig. 4).  We also report the results of our investigations into the antibacterial 
properties of this formulation against several bacterial strains.  Furthermore, we explore the 
abilities of the micro/nanofibre matrix to prevent the formation of S. aureus biofilms, as well as 
the ability to eradicate preformed biofilms, a condition which is more closely related to infections 
in wounds and therefore relevant to translational research of novel wound dressings. 
 
 
Fig. 4.  Diameter of inhibition zone in the MRSA susceptibility test of 3L+tet 5% demonstrating 
antibacterial efficacy of 3L+tet 5% after 14 days of release.  The error bars represent the standard 
deviation (n = 3, duplicate replicates). 
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Testing the formulations against a panel of bacteria 
 
Organism Positive control 
Zone of inhibition (mm) 
3% matrices 
Zone of inhibition (mm) 
B. subtilis 168 32.9 ± 4.1 28.9 ± 5.6 
E. coli NTB5 28.1 ± 0.8 24.9 ± 1.4 
E. faecalis ATCC 19433 28.2 ± 0.5 28.1 ± 0.9 
E. faecalis BS385 22.5 ± 0.8 23.1 ± 1.5 
P. aeruginosa NCTC 6750 8.8 ± 0.9 6.7 ± 0.8 
P. aeruginosa PA01 11.2 ± 0.2 9.9 ± 1.0 
S. aureus MRSA252 36.5 ± 0.7 33 ± 2.4 
S. typhimurium NTB6 23.5 ± 0.6 20.9 ± 2.1 
 
Table 1.  The antibacterial activity of 3L+tet 3% matrices against a panel of eight bacterial strains. 
 
In total, eight bacterial strains, including three laboratory strains and five clinical isolates, were 
tested.  B. subtilis 168 is a very well characterised laboratory strain [21].  The E. coli NTB5 and S. 
typhimurium NTB6 strains are clinical isolates obtained from the collection of the Radboud 
University Nijmegen Medical Centre [22].  E. faecalis ATCC 19433 is a commonly used 
reference strain, whereas E. faecalis BS385 is a clinical isolate obtained from biliary stents [23].  
Similarly, P. aeruginosa NCTC 6750 is a reference strain, whereas P. aeruginosa PAO1 is well-
characterised clinical strain originally isolated from a wound [24].  Finally, S. aureus MRSA252 
is a multidrug-resistant clinical isolate that is a representative of an epidemic lineage endemic in 
UK hospitals.  This MRSA is resistant to several antibiotics, including penicillin, ciprofloxacin, 
erythromycin, and meticillin [25].  With the exception of the P. aeruginosa strains, which have a 
significant level of intrinsic resistance, all strains are sensitive to tetracycline.  All strains were 
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tested against the 3L micro/nanofibre matrices using disc diffusion tests, and compared to 
commercially available tet discs.  As shown in Table 1, there are no significant differences (P > 
0.01) in the effectiveness of the matrices and in comparison to the commercial tet discs used.  Not 
unexpectedly, the PCL without tet (negative control) showed no effect (data not shown). 
 
Biofilms studies 
 
The different 3L+tet containing matrices were assessed for their efficacy in preventing biofilm 
formation as well as in eradicating pre-formed biofilms.  For the biofilm assays, we used S. aureus 
MRSA252 which is a good biofilm-forming clinical isolate.  Initial assessment using the most-
commonly used biofilm model, the microtiter plate (MTP) assay.  In this assay, bacteria are grown 
in broth in the wells of a polystyrene 96-well plate.  The cells adhere to the bottom of the well and 
form biofilms there.  The amount of biofilm present is assessed using crystal violet staining. 
 
MTP (96-well microtiter plate) biofilm assay 
 
The first MTP assay measured prevention of biofilm growth by S. aureus MRSA252.  As shown 
in Fig. 5, at 24 h, tet was indeed efficient in preventing biofilm formation (A595 = 0.11 ± 0.1 for 
biofilms formed in the presence of 3L+tet, versus A595 = 1.80 ± 0.67 for biofilms formed in the 
presence of cells only, P < 0.01).  There was no significant effect of PCL nanofibres on biofilm 
formation (A595 = 1.83 ± 0.62 for biofilms formed in the presence of PCL no tet versus A595 = 
1.80 ± 0.62 for biofilms formed in the presence of cells only, P > 0.01).  Our formulation of 
3L+tet micro/nanofibre matrices showed comparable activity to the control (A595 = 0.11 ± 0.1 for 
biofilms formed in the presence of 3L+tet versus A595 = 0.13 ± 0.06 for biofilms formed in the 
presence of tet, P < 0.01). 
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Fig. 5.  Prevention of biofilm formation tested using the MTP model.  The tet solution is prepared 
to contain the same amount as the 3L+tet 3% sample.  The error bars represent the standard 
deviation (n = 3, 6 replicates). 
 
It is also important in translational research to investigate the activity of the matrices 
against preformed biofilms.  Infected wounds will typically already contain biofilms, and it is 
probably also easier to prevent biofilm formation than to kill an existing biofilm.  This assessment 
was done with an MTP assay in which biofilms were first grown for 24 h, after which fresh 
medium was added to the wells with or without tet matrices.  This was followed by another 24 h 
incubation and then the amount of biofilm was again quantified.  As shown in Fig. 6, the 3L+tet 
matrices showed significant antibacterial activity against S. aureus MRSA252 biofilms (A595 = 
0.27 ± 0.13 for biofilms + 3L+tet versus A595 = 3.49 ± 1.48 for biofilms formed in the presence of 
cells only, P < 0.01). 
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Fig. 6.  The activity of the matrices against formed biofilms (n = 3) tested using the MTP model.  
The tet solution is prepared to contain the same amount as the 3L+tet 3% sample.  The error bars 
represent the standard deviation (n = 3, 6 replicates). 
 
Killing biofilms by sustained release of tet 
 
 
Fig. 7.  The activity of the matrices against formed biofilms (normalised absorbance) tested using 
the MTP model.  The error bars represent the standard deviation (n = 3, 6 replicates). 
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Fig. 8.  Diameter of the inhibition zone in the MRSA susceptibility test of 3L+tet 3%.  The error 
bars represent the standard deviation (n = 3, duplicate replicates). 
 
 
Fig. 9.  The activity of the matrices against formed biofilms tested using the MTP model.  The 
error bars represent the standard deviation (n = 3, 3 replicates).  The left-hand columns represent 
the samples where the discs were left in the wells for 3 days, whereas the right-hand columns 
represent the samples where the discs were left in the wells for 1 day. 
 
In order to test whether the sustained release of tet from 3L+tet 3% was effective against biofilms, 
discs were placed on preformed MRSA252 biofilms and incubated for 24 h.  On day 2, the same 
discs were then transferred to fresh biofilms, and this was repeated on day 3.  All biofilms were 
quantified with crystal violet.  As can be seen in Fig. 7, all discs tested continued to kill preformed 
biofilms for 3 days.  For the first two days there was no significant difference between the 
different types of discs.  However, after 3 days the efficacy of 3L+tet 3% was clearly better than 
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single layer 3% or commercial tet discs, with 3L+tet 3% killing approximately 84% of the 
biofilms, whereas the other discs killed around 65% of the MRSA252 biofilms. 
The discs that were on biofilms for three consecutive days were then tested for two further 
days in the Kirby-Bauer disc diffusion assay, again using S. aureus MRSA252.  On day 4, the 
zones of inhibition observed for 3L+tet 3% and commercial discs were similar.  However, on day 
5, when these discs were again transferred to agar freshly inoculated with MRSA252, the 
commercial tet discs were clearly exhausted as with these only a very small zone of inhibition was 
observed, whereas the 3L+tet 3% discs still gave rise to zones of inhibition of ~11 mm (Fig. 8).  
This clearly showed that 3L+tet 3% discs were continuously active over a period of at least 5 days 
on both biofilms and planktonic cells.  The sustained antibiotic activity of the tet (5%) matrices 
against formed biofilms was further tested using the MTP model.  In Fig. 9, the left-hand columns 
show prevention of growth over 3 days, in comparison with 1 day (the right-hand columns). 
 
Confocal microscopy 
To analyse the efficacy of the matrices more qualitatively, biofilms were grown on polyvinyl 
coverslips in broth and treated both with and without the drug-containing fibrous matrices.  The 
biofilms were then analysed using the LIVE/DEAD BacLight stain which is composed of two 
fluorescent dyes that stain nucleic acids:  SYTO 9 and propidium iodide (Fig. 10).  SYTO 9 
penetrates bacterial membranes whether they are alive (with intact cell membranes) or dead 
(having damaged membranes), causing them to fluoresce green.  However, propidium iodide, 
which is at least doubly positively charged, only penetrates bacteria with damaged membranes 
and its subsequent interaction with nucleic acids results in red fluorescence.  When adding SYTO 
9 together with propidium iodide both will penetrate dead cells but, due to the higher affinity of 
propidium iodide for nucleic acids, the cells fluoresce red.  Fig. 11 shows the effect of the tet-
loaded matrices in killing bacteria even when they are presented in biofilms.  The treated 
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coverslip clearly fluoresces red at a level comparable to that of the tet control, which indicates that 
the bacteria are dead, whereas the untreated coverslip fluoresces green showing that the bacteria 
are alive [31]. 
 
	   	  
Propidium iodide	   	   	   	  	  	  	  SYTO 9 
Fig. 10.  The two fluorescent dyes in LIVE/DEAD BacLight stain. 
 
     
Fig. 11.  Confocal microscopy images of biofilms grown on coverslips, from left to right:  
coverslip treated with 3L+tet 3% matrix, untreated coverslip, coverslip treated with a filter paper 
+ tet loaded with the same amount as 3L+tet 3% matrix as a control. 
 
Colony biofilm model (CBM) 
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The biofilm model used in the MTP assay is a fairly simple system in which the biofilm grows in 
liquid broth.  A model more closely resembling biofilms growing in a wound is the colony biofilm 
model (CBM).  In this model, biofilms are grown on a polycarbonate membrane that sits on top of 
an agar plate.  This in vitro biofilm model follows from studies by Stewart and co-workers in 
simulating two aspects of the wound environment:  low fluid shear and proximity to an air 
interface.  The CBM captures the geometry of nutrient delivery to a biofilm in a wound in which 
carbon and nitrogen sources emanate from the host tissue (agar in this model) with oxygen 
supplied from the opposite side of the biofilm by diffusion into the biofilm from the air interface 
[28, 32].  This more complex model also has the advantage that it is easy to enumerate the number 
of live bacteria, as the membrane can simply be taken off the agar plate and cells can then be 
resuspended in liquid medium.  Using this, we investigated the antibacterial activity of the tet 
matrices against well-developed 72 h-mature biofilms. 
 
 
Fig. 12.  Effects of the tet (3% and 5%) containing matrices on biofilms grown on polycarbonate 
discs tested using the CBM model expressed as normalised live bacteria/disc.  The filter disc 
(Whatman 3MM Chr, 0.34 mm thickness) was loaded (by evaporation of a methanolic solution) 
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with an amount of tet equivalent to the 3L+tet 3% sample loading.  The error bars represent the 
standard deviation (n = 3). 
 
Fig. 12 clearly demonstrates the antibacterial effectiveness of the formulations.  Compared with 
the control biofilms, the 3% and 5% tet samples reduced the number of living cells in the biofilms 
on the polycarbonate discs significantly; the CFU/disc was reduced from 100% for untreated 
biofilms to 35% for the 3% tet sample (P < 0.01).  There is a significant further reduction in 
CFU/disc achieved with the 5% tet sample (down to 21%, P < 0.01) compared to that obtained 
with the 3% tet sample. 
One key question was whether the 3L+tet matrix showed reduced efficacy compared to 
commercial tet discs against a panel of bacteria in the Kirby-Bauer disc diffusion test.  Our 
matrices showed good-excellent antibacterial activity (Table 1).  In our experiments, antibacterial 
susceptibility tests against our panel of different, clinically relevant species of bacteria determined 
these to be sensitive to tet loaded in the triple-layer fibrous matrix, where our formulation 
encapsulates a part of the antibiotic in the matrix to achieve initially a burst and then a sustained 
release which, even after 14 days, was sufficient to kill bacteria (Fig. 4).  Although in vitro testing 
cannot be directly correlated to in vivo performance, in vitro models are valuable as they allow 
simple, rapid, and inexpensive screening of anti-biofilm agents [33].  Furthermore, improving the 
efficacy of traditional wound-care products against biofilms will significantly aid in the discovery 
and selection of novel and appropriate therapies [33]. 
Several studies have evaluated the effects of wound dressings against both planktonic and 
biofilm bacterial phenotypes as both of them are present in wounds [34-37], but not all 
antibacterials that are used clinically and successfully against planktonic bacteria kill biofilms.  
For example, Percival et al. have observed an enhanced tolerance to silver alginate dressing when 
a selected number of microorganisms were grown in the biofilm phenotypic state compared to 
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their non-biofilm counterparts [34, 35].  Hill et al. reported that neither ciprofloxacin nor 
flucloxacillin could disrupt mixed Pseudomonas and Staphylococcus biofilms, while only two of 
six silver-containing dressings showed effects on biofilms grown for 3 days [36].  Hess et al. 
demonstrated that after incubating S. aureus RN6390 and ATCC 25923 biofilms with high 
concentrations of gentamicin, the S. aureus remained viable and biofilm biomass increased [37].  
Similarly, we have found that both gentamicin and vancomycin are very inefficient in eradicating 
preformed S. aureus MRSA252 biofilms (data not shown).  Here we show that 3L+tet fibrous 
matrices significantly decrease the biomass of biofilms formed with S. aureus MRSA252.  This 
decrease was demonstrated quantifiably using crystal violet in the MTP assay reducing the 
biomass of a 24 h-biofilm by more than 90%.  This was also confirmed qualitatively using the 
BacLight stain which showed that this 3L+tet fibrous matrix released tet and killed the bacteria 
rather than dispersing the biofilm.  The confocal microscopy images (Fig. 11) provide further 
support to the MTP assay results that the majority of the bacteria did not survive treatment with 
the 3L+tet fibrous matrix.  In the MTP assay, using the non-specific dye crystal violet, both dead 
and living cells are stained [38], whereas the BacLight stain distinguishes between live and dead 
cells [31]. 
We then examined whether the 3L+tet matrix is capable of eradicating biofilms grown in 
conditions that more resemble the wound environment.  For this we used the CBM assay which is 
more complex than the MTP assay in that the biofilms grow and mature at an air interface on a 
polycarbonate disc and nutrients are provided from below [33].  We also investigated a higher 
concentration (5%) of tet in our sustained release matrices in order to ensure efficacy against 
biofilms in this more complex model.  The CBM model showed that the 3L+tet 5% matrix 
decreased the viable count in a 72 h-mature biofilm by about 80% (Fig. 12).  The residual 20% 
may be targeted by the host immune system and/or by the sustained released of tet.  Bacterial 
resistance shown in biofilms is mainly caused by the protection afforded by the biofilm to the 
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bacteria against the host immune system, environmental stress, and antibiotics [4, 5, 33, 39].  For 
example, Kostenko et al. showed that biofilm bacteria, which survived the initial silver treatment, 
were susceptible to tobramycin, ciprofloxacin and trimethoprim-sulfamethoxazole, in contrast to 
untreated biofilms, which were highly tolerant to the same antibiotics [40]. 
In each of our different in vitro models, with increasing levels of biofilm complexity, the 
effectiveness of the tet-loaded triple-layer fibrous matrix was similar to the positive tet control, 
thus even retaining a part of the loaded dose of the tet for sustained release did not lower the 
initial bacterial killing capability.  Using these established models, we have shown that our 
formulations of tet-loaded triple fibrous matrix are anti-biofilm agents capable of eradicating 
biofilms made by S. aureus MRSA252 a multidrug-resistant clinical isolate that is a representative 
of an epidemic lineage endemic in UK hospitals. 
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